Poulton Jeffrey V.

CFO Poulton sells 2,468 shares at avg $323.08; stock now -30% over 90 days vs blended price.

Jeffrey V. Poulton, EVP and Chief Financial Officer of Alnylam Pharmaceuticals, executed 8 separate sales totaling 2,468 shares for $797,350.54 on 2026-03-04, at a blended average price of $323.08. The current price of $320.66 is -30.0% over the past 90 days and -8.9% over the past 30 days, trading -34.7% below its 52-week high of $491.22. His post-transaction holding of 61,805 shares represents a -3.8% reduction from prior holdings. The timing warrants observation: his recent same-ticker activity on 2026-03-02 involved 5 prior sales (outcomes not yet measurable), and his cross-ticker track record shows an average 30-day return of -11.0% following 20 prior open-market sells, suggesting a pattern of selling into weakness rather than strength. The company's fundamentals—annual revenue growth of +65.2%, net income of $251,084,000.00, and a P/E of 66.94—indicate a high-growth, high-valuation profile, yet the stock has declined sharply in recent months.

CFO Poulton sells 2,206 shares of ALNY for $722,800.78 across 10 transactions on 2026-03-02

Jeffrey V. Poulton, EVP and Chief Financial Officer of Alnylam Pharmaceuticals, executed 10 separate sales totaling 2,206 shares for $722,800.78 at a blended average price of $327.65 on March 2, 2026, reducing his holdings by 3.3% to 64,273 shares. The sale occurred as the stock trades 33.4% below its 52-week high of $491.22, down 3.5% over the past 30 days and 29.7% over the past 90 days. Poulton's cross-ticker track record shows 20 prior open-market sales with an average 30-day return of -11.3%, though same-ticker measurable outcomes at ALNY are not yet available. The company's fundamentals remain strong with annual revenue growth of 65.2%, positive net income of $251,084,000.00, and a market cap of $43,407,555,031.20, though the P/E of 68.33 reflects growth premium valuation.

CFO Poulton sells 2,242 shares at $310.08; stock down 7.4% in 30 days, 27.8% in 90 days post-transaction

Jeffrey V. Poulton, EVP and Chief Financial Officer, sold 2,242 shares of ALNY at $310.08 on 2026-02-13, reducing his holdings by 3.6% to 59,802 shares. The stock has subsequently declined 7.4% over 30 days and 27.8% over 90 days from the sale date. His prior five trades at ALNY, all conducted on 2026-01-12, show 30-day declines ranging from -12.0% to -13.9%, establishing a consistent pattern of sells followed by near-term weakness. This cumulative pattern—the current transaction combined with prior ALNY sales and his cross-ticker track record of -11.5% average 30-day returns on sells—suggests either prescient timing or systematic positioning adjustments that warrant investor scrutiny of recent operational developments.

CFO Jeffrey Poulton sells 2,780 shares at avg $362.87 for $1.0M; stock down 23.7% in 90 days, now -25.3% from 52-week high.

Jeffrey Poulton, EVP and CFO of Alnylam Pharmaceuticals, executed 21 separate sales totaling 2,780 shares for $1,008,765.87 on 2026-01-12, reducing his holdings by 4.6% to 57,465 shares. The multi-tranche execution across a narrow price range ($353.95–$375.65) occurred as ALNY's stock has declined 23.7% over 90 days and sits 25.3% below its 52-week high of $491.22. His prior trades at ALNY show a strong pattern: all 5 preceding sales were well-timed at the 90-day mark, with cumulative 90-day returns ranging from -13.1% to -11.0%—confirming the stock fell after each exit. His cross-ticker track record shows a 95.00% well-timed rate on 20 prior sells, with an average 90-day return of -7.5%, suggesting consistent ability to sell into weakness or before declines. The current sale occurs during an active market decline, adding to a pattern of disciplined execution at ALNY during downward pressure.

CFO Jeffrey V. Poulton sold 3,821 shares for $1.7M on 2025-10-02, reducing holdings by 6.6%

Poulton executed 12 separate sales totaling 3,821 shares for $1,727,283.60 on a single date, with transaction prices ranging from $446.53 to $457.64 and a blended average of $452.05. The current price of $456.35 is +5.6% above the blended transaction average, suggesting the insider sold below current market levels. His post-transaction holdings of 54,052 shares represent a 6.6% reduction from prior holdings of 57,873 shares, indicating a material but non-complete exit. At Alnylam specifically, Poulton's prior five sales on 2025-08-18 showed mixed near-term performance with 30-day returns ranging from -0.9% to +0.4%, and no measurable 90-day outcomes yet. The company reported net income of $-66,277,000.00 in its most recent full fiscal year despite revenue growth of +23.0% to $773,689,000.00, showing ongoing unprofitability that may be relevant to capital allocation decisions by management.

CFO Poulton sells 2,274 shares ($1.0M) across 8 transactions; holds 50.1K shares post-sale at stock near 52-week high.

Poulton Jeffrey V., CFO of ALNYLAM PHARMACEUTICALS, executed 8 separate sales totaling 2,274 shares for $1,030,727.12 on 2025-08-18, with a blended average price of $453.27 against a current price of $458.28 (stock at 52-week high). The sales represent a -4.3% reduction from his pre-transaction holdings of 52,395 shares, leaving him with 50,121 shares post-transaction. His cross-ticker track record shows 6 prior sells with a 90-day well-timed rate of 100.00%, and at ALNY specifically, all 5 prior sells were well-timed at the 90-day mark, though those 2023 sales occurred when the stock subsequently declined. The company is unprofitable (net income of $-66,277,000 over the latest full fiscal year) despite strong revenue growth of +23.0% and a $773.7M quarterly revenue base. The insider remains a substantial holder with 50.1K shares post-sale, and the transaction timing occurs as the stock trades at its 52-week high following a 43.0% gain over the prior 30 days and a 56.6% gain over the prior 90 days, suggesting a significant run-up in valuation since the transaction execution.